What do we know about the variability in survival of patients with amyotrophic lateral sclerosis?

Amyotrophic lateral sclerosis epidemiology genetics immune system metabolism natural history neurodegeneration survival

Journal

Expert review of neurotherapeutics
ISSN: 1744-8360
Titre abrégé: Expert Rev Neurother
Pays: England
ID NLM: 101129944

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 23 6 2020
medline: 12 6 2021
entrez: 23 6 2020
Statut: ppublish

Résumé

ALS is a fatal neurodegenerative disease. However, patients show variability in the length of survival after symptom onset. Understanding the mechanisms of long survival could lead to possible avenues for therapy. This review surveys the reported length of survival in ALS, the clinical features that predict survival in individual patients, and possible factors, particularly genetic factors, that could cause short or long survival. The authors also speculate on possible mechanisms. a small number of known factors can explain some variability in ALS survival. However, other disease-modifying factors likely exist. Factors that alter motor neurone vulnerability and immune, metabolic, and muscle function could affect survival by modulating the disease process. Knowing these factors could lead to interventions to change the course of the disease. The authors suggest a broad approach is needed to quantify the proportion of variation survival attributable to genetic and non-genetic factors and to identify and estimate the effect size of specific factors. Studies of this nature could not only identify novel avenues for therapeutic research but also play an important role in clinical trial design and personalized medicine.

Identifiants

pubmed: 32569484
doi: 10.1080/14737175.2020.1785873
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

921-941

Auteurs

Pamela A McCombe (PA)

Centre for Clinical Research, The University of Queensland , Brisbane, Australia.
Department of Neurology, Royal Brisbane and Women's Hospital , Brisbane, Australia.

Fleur C Garton (FC)

Institute for Molecular Biosciences, The University of Queensland , Brisbane, Australia.

Matthew Katz (M)

Department of Neurology, Royal Brisbane and Women's Hospital , Brisbane, Australia.

Naomi R Wray (NR)

Institute for Molecular Biosciences, The University of Queensland , Brisbane, Australia.
Queensland Brain Institute, The University of Queensland , Brisbane, Australia.

Robert D Henderson (RD)

Centre for Clinical Research, The University of Queensland , Brisbane, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH